Since MEK mutations are rare in human cancer and MEK1 inhibitors show normal tissue toxicity in cancer therapy,16 MEK inhibitors are commonly used clinically in combination with BRAF inhibitors. This evidence concerns the gene MAP2K1 and cancer.